This is what the gateway will look like once the work is complete Work has begun to create a high-quality incubator space in the heart of The London Cancer Hub in Sutton. The space - known as Innovation Gateway - is a significant step in The London Cancer Hub development, which aims to create the world’s leading district for cancer research, treatment and commercial enterprise. The Innovation Gateway will offer companies the chance to work side by side with world-class scientists at The Institute of Cancer Research (ICR) within mixed laboratory, office and collaboration space. It is due to open in late 2021 and will be home to a range of companies related to cancer, with a particular emphasis on accommodating start-ups, spin-outs and small teams from the biotech, medtech, data science and pharmaceutical industries.
TORONTO The United Nations has issued a new warning about starvation in Yemen, calling it one of the worst famines the world has seen where the level of suffering is so staggering the head of the World Food Program (WFP) says it is a disgrace on humanity. WFP Executive Director David Beasley recently visited Yemen and said he was horrified by what he saw. I m standing here in this hospital room where this child, literally, is on the verge of death. In fact, 400,000 children are at risk of dying right now, Beasley told reporters on Wednesday. It s a horrible situation. It s a disgrace on humanity what’s happening here, he added.
E-Mail
Cancers that are resistant to radiotherapy could be rendered susceptible through treatment with immunotherapy, a new study suggests.
Researchers believe that manipulating bowel cancers based on their immune landscape could unlock new ways to treat resistant tumours.
Cancers can evolve resistance to radiotherapy just as they do with drugs.
The new study found that profiling the immune landscape of cancers before therapy could identify patients who are likely to respond to radiotherapy off the bat, and others who might benefit from priming of their tumour with immunotherapy.
Scientists at The Institute of Cancer Research, London, in collaboration with the University of Leeds and The Francis Crick Institute, studied inflammation in bowel tumour samples taken before and after radiotherapy from 53 patients. They aimed to understand how tumour immune activity before and after radiotherapy differs between patients who respond well and those who respond poorly to treatment.
Blood test picks out prostate cancer drug resistance 04
Blood test picks out prostate cancer drug resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
The new research paves the way for information from a blood test to inform prostate cancer treatment in future, with only those patients whose cancers are free of resistance mutations taking the drug, abiraterone.
The study is also a proof of principle that tests for cancer DNA in the bloodstream can be used to detect drug resistance mutations – allowing patients who will not benefit from one drug to be given an alternative treatment instead.